Ascendis Pharma A (ASND) Change in Account Payables (2014 - 2026)

Ascendis Pharma A has reported Change in Account Payables for 13 years, with the latest figure at -$24.6 million in Q1 2026.

• Quarterly Change in Account Payables rose 42.53% year-over-year to -$24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.9 million (down 540.89% YoY) and the FY2025 annual result came in at -$49.2 million, down 270.85% from the prior year.
• Change in Account Payables fell to -$24.6 million in Q1 2026 per ASND's latest filing, from -$10.7 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $48.1 million in Q4 2024 and troughed at -$42.9 million in Q1 2025.
• A 5-year average of $535476.0 and a median of -$4.9 million in 2022 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 544.5% in 2024, down 275.44% in 2024.
• Over 5 years, Change in Account Payables stood at $23.9 million in 2022, then sank by 145.28% to -$10.8 million in 2023, then jumped by 544.5% to $48.1 million in 2024, then sank by 122.28% to -$10.7 million in 2025, then sank by 130.03% to -$24.6 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$24.6 million, -$10.7 million, and -$8.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.